Checkpoint Inhibitor-Associated Myasthenia–Myositis Overlap With Neuromuscular Respiratory Failure After Dual PD-L1 Plus CTLA-4 Checkpoint Blockade for Hepatocellular Carcinoma. Here, CTLA4 is linked to Fatigable weakness.